• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Clene Inc.

    9/8/23 6:47:12 PM ET
    $CLNN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CLNN alert in real time by email
    SC 13G 1 ci-sc13g_06162023.htm SCHEDULE 13G


    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549

    SCHEDULE 13G
    (Rule 13d-102)

    INFORMATION TO BE INCLUDED
    IN STATEMENTS FILED PURSUANT
    TO RULES 13d-1(b), (c), AND
    (d) AND AMENDMENTS THERETO
    FILED PURSUANT TO RULE 13d-2

    Under the Securities Exchange Act of 1934


    Clene Inc.
    (Name of Issuer)
     
    Common Stock, $.0001 par value per share
    (Title of Class of Securities)
     
    G8959N130
    (CUSIP Number)
     
     June 16, 2023
    (Date of Event Which Requires Filing of this Statement)
     
    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☐ Rule 13d-1(b)
    X Rule 13d-1(c)
    ☐ Rule 13d-1(d)

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
     

     

    CUSIP No. G8959N130
    Page 2 of 6 pages
       


    1
    NAMES OF REPORTING PERSONS
     
     
     
    Chidozie Ugwumba
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
       
    (a)☐
       
    (b) [X]
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
     United States
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    5
    SOLE VOTING POWER
     
     
     
    28,018,908 (1)(2)
     
     
     
     
    6
    SHARED VOTING POWER
     
     
     0
     
     
     
     
    7
    SOLE DISPOSITIVE POWER
     
     
     
    28,018,908 (1)(2)
     
     
     
     
    8
    SHARED DISPOSITIVE POWER
     
     
     0
     
     
     
     
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
     
    28,018,908 (1)(2)
     
     
     
     
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
     
    ☐
     
     
     
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
     
     19.9%(2)
     
     
     
     
    12
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
     IN
     
     
     
     
     
    (1)The number represents (i) 13,018,908 shares of common stock, par value $0.0001 per share (the “Common  Stock”) of Clene, Inc. (the “Issuer”) as of September  8, 2023, (ii) 7,500,000 shares of Common Stock issuable upon exercise of Tranche A Warrants that are immediately exercisable, and (iii) 7,500,000 shares of Common Stock issuable upon exercise of Tranche B Warrants that are immediately exercisable within 60 days of this Statement, based on 128,404,735 shares of the Issuer’s Common Stock issued and outstanding as of August 10, 2023.

    (2)The Tranche A Warrants and Tranche B Warrants contain provisions preventing the Warrants from being exercised if such exercise would result in the holder obtaining greater than 19.9% of the Issuer’s voting securities. However, the amounts reported in rows 5, 7 and 9 herein represent the number of shares of Common Stock that would be issuable upon exercise of the Tranche A Warrant and Tranche B Warrant in full, and do not give effect to the blocking provisions.

    CUSIP No. G8959N130
    Page 3 of 6 pages
       

    Schedule 13G

    Chidozie Ugwumba (the “Reporting Person”) previously filed reports on Schedule 13D. However, on February 15, 2023, the Reporting Person resigned from the board of directors of Clene, Inc. (the “Issuer”). As of February 15, 2023, and the date hereof, the Reporting Person holds securities of the Issuer in the ordinary course of business without the purpose of or with the effect of changing or influencing the control of the Issuer and does not hold such securities in connection with or as a participant in any transaction having that purpose of effect. This Schedule 13G includes disclosures for which a Schedule 13G was previously inadvertently not filed by the Reporting Person within 10 days of the acquisition of beneficial ownership of certain equity securities of the Issuer on June 16, 2023.


    Item 1(a). Name of Issuer:
     
    Clene Inc. (the "Issuer")
     
    Item 1(b). Address of Issuer's Principal Executive Offices:
     
    6550 South Millrock Drive, Suite G50, Salt Lake City, Utah

    Item 2(a)-(c).
    Name of Person Filing:

    (a) – (c) Name of Persons Filing; Address; Citizenship:

    This statement is being filed by Chidozie Ugwumba (the “Reporting Person”). The Reporting Person’s principal business address is c/o SymBiosis Capital Management, LLC 609 SW 8th St., Suite 510, Bentonville, AR 72712. The citizenship of the Reporting Person is the United States of America.



    Item 2(d). Title of Class of Securities:

     Common Stock, par value $0.0001 per share (“Common Stock”).
     
    Item 2(e). CUSIP Number:
     
    G8959N130


    CUSIP No. G8959N130
    Page 4 of 6 pages
       

    Item 3. If This Statement Is Filed Pursuant to Sections 240.13d-1(b) or
    240.13d-2(b) or (c), Check Whether the Person Filing Is a(n):

    Not applicable


    (a) ☐ Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o);


    (b) ☐ Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c);


    (c) ☐ Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c);


    (d) ☐ Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);


    (e) ☐ Investment adviser in accordance with Section 240.13d-1(b)(1)(ii)(E);


    (f) ☐ Employee benefit plan or endowment fund in accordance with Section 240.13d-1(b)(1)(ii)(F);


    (g) ☐ Parent holding company or control person in accordance with Section 240.13d-1(b)(1)(ii)(G);


    (h) ☐ Savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);


    (i) ☐ Church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);


    (j) ☐ A non-U.S. institution in accordance with Section 240.13d-1(b)(1)(ii)(J);


    (k) ☐ Group, in accordance with Section 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with Section 240.13d-1(b)(1)(ii)(J), please specify the type of institution: ____________________________ .
     
    Item 4. Ownership.


    (a) and (b)
    Amount beneficially owned: 
    The information set forth in rows 5 through 11 of the cover pages is incorporated by reference into this Item 4.

    The shares reporting in this Schedule 13G include (i) 13,018,908 shares of Common Stock of the issuer, (ii) 7,500,000 shares of Common Stock issuable upon exercise of Tranche A Warrants that are immediately exercisable, and (iii) 7,500,000 shares of Common Stock issuable upon exercise of Tranche B Warrants that are immediately exercisable within 60 days of this Statement, based on 128,404,735 shares of the Issuer’s Common Stock issued and outstanding as of August 10, 2023.

    The Tranche A Warrants and Tranche B Warrants contain provisions preventing the Warrants from being exercised if such exercise would result in the holder obtaining greater than 19.9% of the Issuer’s voting securities. However, the amounts reported in this Item 4 represent the number of shares of Common Stock that would be issuable upon exercise of the Tranche A Warrant and Tranche B Warrant in full, and do not give effect to the blocking provisions.





    (c) Number of shares as to which the person has:




    CUSIP No. G8959N130
    Page 5 of 6 pages
       


    Reporting Person
     
    Sole Voting Power
     
     
    Shared Voting Power
     
     
    Sole Dispositive Power
     
     
    Shared Dispositive Power
     
     
    Percentage of Common Stock Outstanding
     
    Chidozie Ugwumba
     
     
    28,018,90
     
     
     
    0
     
     
     
    28,018,90
     
     
     
    0
     
     
     
    19.9
    %*
     
     
    *
    The percent of class was based on 128,404,735 shares of the Issuer’s Common Stock issued and outstanding as of August 10, 2023, plus the shares of Common Stock exercisable upon exercise of Tranche A Warrants and Tranche B warrants, after giving effect to the blocking provisions described above, which prevent the Reporting Persons from exercising the Tranche A Warrants and the Tranche B Warrants in excess of 19.9% of the Issuer’s voting securities.
         


    Item 5. Ownership of Five Percent or Less of a Class.

    Not applicable.


    Item 6.
    Ownership of More Than Five Percent on Behalf of Another Person.

    Not applicable

     
    Item 7.
    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.

    Not applicable
     

    Item 8.
    Identification and Classification of Members of the Group.

    Not applicable
     

    Item 9.
    Notice of Dissolution of Group.

    Not applicable
     
     
    Item 10.
    Certification.
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.
     


    CUSIP No. G8959N130
    Page 6 of 6 pages
       
    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Dated:  09/08/23
     
     

     
         CHIDOZIE UGWUMBA
         
     

     /s/ Chidozie Ugwumba
       
    Name:  Chidozie Ugwumba
       
     
     
    *The Reporting Person specifically disclaims beneficial ownership of the securities referenced herein except to the extent of his pecuniary interest therein.
     

     

    Get the next $CLNN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CLNN

    DatePrice TargetRatingAnalyst
    10/4/2022Outperform → Perform
    Oppenheimer
    7/18/2022$16.00Buy
    H.C. Wainwright
    5/2/2022$10.00Buy
    Canaccord Genuity
    9/28/2021$20.00Outperform
    Oppenheimer
    More analyst ratings

    $CLNN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner General Resonance Llc sold $12,092 worth of shares (2,733 units at $4.42), decreasing direct ownership by 0.38% to 710,852 units (SEC Form 4)

      4 - Clene Inc. (0001822791) (Issuer)

      3/19/25 6:47:32 PM ET
      $CLNN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Wilcox Reed N

      4 - Clene Inc. (0001822791) (Issuer)

      2/28/25 4:24:28 PM ET
      $CLNN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Mosca Alison

      4 - Clene Inc. (0001822791) (Issuer)

      2/28/25 4:24:08 PM ET
      $CLNN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CLNN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Clene Inc.

      SC 13G/A - Clene Inc. (0001822791) (Subject)

      11/14/24 3:32:55 PM ET
      $CLNN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Clene Inc.

      SC 13G - Clene Inc. (0001822791) (Subject)

      11/14/24 3:26:45 PM ET
      $CLNN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Clene Inc.

      SC 13D/A - Clene Inc. (0001822791) (Subject)

      10/2/24 4:38:44 PM ET
      $CLNN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CLNN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    $CLNN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Clene downgraded by Oppenheimer

      Oppenheimer downgraded Clene from Outperform to Perform

      10/4/22 8:58:30 AM ET
      $CLNN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • H.C. Wainwright initiated coverage on Clene with a new price target

      H.C. Wainwright initiated coverage of Clene with a rating of Buy and set a new price target of $16.00

      7/18/22 7:19:07 AM ET
      $CLNN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Canaccord Genuity initiated coverage on Clene with a new price target

      Canaccord Genuity initiated coverage of Clene with a rating of Buy and set a new price target of $10.00

      5/2/22 9:11:11 AM ET
      $CLNN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Clene Reports First Quarter 2025 Financial Results and Recent Operating Highlights

      Clene preparing for upcoming meeting in the second quarter with the U.S. Food and Drug Administration (FDA) to reach agreement on its statistical analysis plan (SAP) regarding analysis of neurofilament light chain (NfL) biomarker dataClene collecting NfL biomarker data from its large National Institute of Health (NIH)-sponsored Expanded Access Protocol (EAP), for evaluation in the third quarter to satisfy the FDA recommendation for additional NfL dataClene reported new data supporting the remyelination and neuronal repair associated with CNM-Au8® treatment in a late-breaking science session at the American Academy of Neurology (AAN) 2025 Annual MeetingClene released new data from a cross-reg

      5/7/25 8:00:00 AM ET
      $CLNN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Presenting on Emerging Growth Conference 81 Day 2 on April 17; Register to live stream

      MIAMI, April 16, 2025 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 80th Emerging Growth Conference on April 16 & 17, 2025. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companies to: [email protected] For updates, follow us on Twitter Day 1 - TodayApril 16, 2025 9:00Virtual Lobby opens.Register for the Conference. If you already registered, go back to t

      4/16/25 7:00:00 AM ET
      $ASBP
      $BENF
      $BNZI
      $CIA
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Finance: Consumer Services
      Finance
    • Presenting on Emerging Growth Conference 81 Day 1 on April 16; Register to live stream

      MIAMI, April 15, 2025 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 81th Emerging Growth Conference on April 16 & 17, 2025. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companies to: [email protected] For updates, follow us on Twitter Day 1April 16, 2025 9:00Virtual Lobby opens.Register for the Conference. If you already register

      4/15/25 7:00:00 AM ET
      $ASBP
      $BENF
      $BNZI
      $CIA
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Finance: Consumer Services
      Finance

    $CLNN
    Financials

    Live finance-specific insights

    See more
    • Clene Reports Topline Results Demonstrating Survival Signal for CNM-Au8® in Healey ALS Platform Trial

      The primary endpoint of adjusted ALSFRS-R and secondary endpoints of CAFS and SVC were not met at 24 weeksPrespecified exploratory analyses of the secondary survival endpoint for the 30 mg dose demonstrated a >90% reduction in risk of death or risk of death/permanently assisted ventilation at 24 weeks Survival signal consistent with prior results from the Phase 2 RESCUE-ALS trialClene will continue the open-label extension of CNM-Au8 in the Healey ALS Platform Trial and is in discussions with the Healey & AMG ALS Center to design and offer an Expanded Access Protocol (EAP) of CNM-Au8 30mg for eligible participants of closed regimens and othersClene is pursuing multiple paths, including ongoi

      10/3/22 8:00:00 AM ET
      $CLNN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Clene to Report HEALEY ALS Platform Trial Topline Results on Monday, October 3

      SALT LAKE CITY, Sept. 30, 2022 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ:CLNN) along with its subsidiaries "Clene" and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative disease, today announced that it will report topline results of the CNM-Au8® regimen of the HEALEY ALS Platform Trial on Monday, Oct. 3. Clene's management team will host a conference call and webcast to discuss the results. Conference Call and Webcast DetailsTime and Date: 8:30 a.m. EDT on Oct. 3, 2022Investors: 1 (888) 660-6179 (toll-free) or 1 (929) 203-1946 (toll)Conference ID: 5318408Webcast Link A live audio

      9/30/22 4:12:25 PM ET
      $CLNN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Clene Reports Positive Topline Results for CNM-Au8® in the Phase 2 VISIONARY-MS Trial in Multiple Sclerosis

      CNM-Au8 met primary and secondary endpoints of Low Contrast Letter Acuity (LCLA) and modified Multiple Sclerosis Functional Composite (mMSFC) compared to placebo over 48 weeks in the mITT populationConsistent improvements favoring CNM-Au8 were seen across paraclinical biomarkers, providing physiological evidence for its potential neuroprotective and remyelinating effectsCNM-Au8 treatment was well-tolerated, and there were no significant safety findings reportedResults provide support to advance CNM-Au8 into Phase 3 clinical developmentClene to host a call and webcast at 7:30 am EDT today SALT LAKE CITY, Aug. 15, 2022 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ:CLNN) (along with its subsidiarie

      8/15/22 7:00:00 AM ET
      $CLNN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CLNN
    SEC Filings

    See more
    • SEC Form 10-Q filed by Clene Inc.

      10-Q - Clene Inc. (0001822791) (Filer)

      5/7/25 8:03:14 AM ET
      $CLNN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Clene Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits

      8-K - Clene Inc. (0001822791) (Filer)

      5/7/25 8:02:01 AM ET
      $CLNN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 424B5 filed by Clene Inc.

      424B5 - Clene Inc. (0001822791) (Filer)

      4/28/25 8:05:38 AM ET
      $CLNN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CLNN
    Leadership Updates

    Live Leadership Updates

    See more

    $CLNN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Clene Appoints Neurology Expert to Executive Team

      SALT LAKE CITY, March 16, 2023 (GLOBE NEWSWIRE) -- Clene, Inc. (NASDAQ:CLNN) along with its subsidiaries "Clene" and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative disease, today announced the appointment of Benjamin Greenberg, M.D., M.H.S. as Head of Medical.    An internationally recognized expert in treating disorders of the central nervous system, Dr. Greenberg brings extensive clinical and research experience to Clene as the company continues its development of CNM-Au8® as a potential treatment for amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS). "Dr. Green

      3/16/23 9:46:10 AM ET
      $CLNN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Clene Announces New Chief Financial Officer Morgan Brown

      SALT LAKE CITY, Feb. 01, 2022 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ:CLNN) along with its subsidiaries "Clene" and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative disease, today announced the appointment of Morgan Brown as Chief Financial Officer effective Feb. 1, 2022. "Morgan joins the executive team at a pivotal time in Clene's growth," stated Clene's President and CEO, Rob Etherington. "He is a seasoned healthcare executive and public-company biopharma CFO, who has led the out-licensing of commercial stage assets and M&A transactions as well as numerous substantial equity and

      2/1/22 7:00:00 AM ET
      $CLNN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Clene Nanomedicine Appoints Dr. Vallerie McLaughlin to its Board of Directors

      SALT LAKE CITY, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ:CLNN) along with its subsidiaries "Clene" and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company dedicated to the treatment of neurodegenerative disease using nanotechnology to treat energetic failure, today announced the appointment of Vallerie V. McLaughlin, MD, to its board as its seventh independent director. Dr. McLaughlin is the Kim A. Eagle MD Endowed Professor of Cardiovascular Medicine, Associate Chief Clinical Officer for Cardiovascular Services of the University of Michigan Medical Group, Associate Chief, Division of Cardiovascular Medicine, and Director of the Pulm

      8/5/21 4:01:00 PM ET
      $CLNN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Matlin David J bought $438,458 worth of shares (92,307 units at $4.75), increasing direct ownership by 26% to 444,491 units (SEC Form 4)

      4 - Clene Inc. (0001822791) (Issuer)

      10/2/24 12:58:21 PM ET
      $CLNN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Science Officer Mortenson Mark bought $97,432 worth of shares (20,512 units at $4.75), increasing direct ownership by 243% to 28,949 units (SEC Form 4)

      4 - Clene Inc. (0001822791) (Issuer)

      10/1/24 4:17:45 PM ET
      $CLNN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Executive Officer Etherington Robert Dee bought $47,500 worth of shares (10,000 units at $4.75), increasing direct ownership by 33% to 40,149 units (SEC Form 4)

      4 - Clene Inc. (0001822791) (Issuer)

      10/1/24 4:17:06 PM ET
      $CLNN
      Biotechnology: Pharmaceutical Preparations
      Health Care